NEW YORK, June 26, 2020 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced an
update to its machine learning driven pancreatic cancer
research.
As previously reported, the Company executed a Scientific
Research Agreement with The University of
Texas Southwestern Medical Center and Cogia BioTech to use
machine learning to find genetic markers in people that indicate an
increased risk of developing pancreatic cancer. This work has
recently identified 100 candidate markers of early and late stage
pancreatic cancer, in human and preclinical models. Moving
forward, the work will stage diagnostic markers, test prognostic
indicators, and help identify drugs best suited for individual
patient treatment.
Anthony Hayes, CEO of AIkido
stated, "Machine learning is an important contributor to this work
and to the future of oncology drug development and treatment, and
the research to date is encouraging. We hope this effort will help
extend life for pancreatic cancer patients."
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to
various risks and uncertainties, including without limitation those
set forth in the Company's filings with the SEC, not limited to
Risk Factors relating to its business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-to-machine-learning-pancreatic-cancer-research-301084406.html
SOURCE AIkido Pharma Inc.